Hematologic Toxicity of Gemcitabine and Cisplatin Combination Therapy in Advanced Urothelial Cancer.
- Author:
Chang Sik JANG
1
;
Jin Seon CHO
;
Sang Kon LEE
;
Young Goo LEE
;
Dae Yul YANG
;
Sung Yong KIM
;
Chang Hee HONG
;
Byung Soo CHUNG
Author Information
1. Department of Urology, Hallym University College of Medicine, Chuncheon, Korea. js315@hallym.or.kr
- Publication Type:Original Article
- Keywords:
Gemcitabine;
Carcinoma;
transitional cell;
Toxicity;
Hematology
- MeSH:
Anemia;
Carcinoma, Transitional Cell;
Cisplatin*;
Doxorubicin;
Drug Therapy;
Hematology;
Hemorrhage;
Humans;
Leukopenia;
Thrombocytopenia;
Vinblastine
- From:Korean Journal of Urology
2003;44(7):672-676
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the hematologic toxicity of gemcitabine and cisplatin (GC) in patients with advanced transitional cell carcinomas. MATERIALS AND METHODS: From 25 patients, with advanced transitional cell carcinomas, 8 had previously received M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for a metastatic disease, and were scheduled to receive gemcitabine, 1,000mg/m2, intravenously, over 30 minutes, on days 1, 8 and 15, and cisplatin, 70mg/m2, over 1 hour, on day 2 of a 28-day cycle. The hematological toxicities of each cycle were evaluated. RESULTS: The main hematological toxicities were thrombocytopenia (grade 3 in 24% and grade 4 in 16% of patients), leukopenia (grade 3 in 14% of patients) and anemia (grade 3 in 12% of patients). Four of the patients that experienced grade 4 thrombocytopenia had a tendency for recurring grade 4 thrombocytopenia during the GC chemotherapy. However, there was no evidence of bleeding. CONCLUSIONS: The most severe hematological toxicity of the GC chemotherapy was thrombocytopenia. The careful observation of the patients that experience grade 4 thrombocytopenia is recommended.
